Corporate Overview
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts
Financial Tear SheetFinancial Tear Sheet
HTMLInvestor Kit
HRTX (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Financial Status IndicatorC
Price$11.01
Change (%) Stock is Up 0.21 (1.94%)
Volume74,213
Data as of 05/01/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Presentation
Download Documentation Corporate Presentation March 19, 2015

Heron Therapeutics, Inc. (NASDAQ: HRTX) is a biotechnology company developing products using its proprietary technology and innovative efforts to develop products to address unmet medical needs. The Company's Biochronomer® polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action of known active ingredients. The Company's lead product, SUSTOL® (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting.

Webcast ImageWebcast - Live
Heron Therapeutics Inc at Bank of America Merrill Lynch 2015 Health Care Conference
05/14/15 at 11:20 a.m. PT
Heron Therapeutics Inc at Bank of America Merrill Lynch 2015 Health Care Conference
Thursday, May 14, 2015 11:20 a.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Recent NewsMore >>
DateTitle 
04/27/15Heron Therapeutics to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Apr. 27, 2015-- Heron Therapeutics, Inc. (NASDAQ:HRTX) announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Bank of America Merrill Lynch Health Care Conference on Thursday, May 14, 2015 at 11:20 a.m. PT in Las Vegas, NV. A live webcast of this presentation will be available on the Company’s website at www.herontx.com in the Investors sectio... 
Printer Friendly Version
04/02/15Heron Therapeutics Reaches Target Patient Enrollment in MAGIC Phase 3 Study of SUSTOL®
-Topline Results Expected in May 2015 -NDA Resubmission Expected Mid-Year 2015 REDWOOD CITY, Calif.--(BUSINESS WIRE)--Apr. 2, 2015-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today announced that it has reached its enrollment target in MAGIC (Modified Absorption Granisetron In the Prevention of Chemotherapy induced nausea and vomiting (CINV)) and is in the process of closing enrollment of new patients at its cli... 
Printer Friendly Version
03/19/15Heron Therapeutics Reports Positive Results From Phase 1 Study of HTX-011
-Results Support Best-in-Class Potential for Lead Candidate for Post-Operative Pain REDWOOD CITY, Calif.--(BUSINESS WIRE)--Mar. 19, 2015-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, announced today positive results from a Phase 1 clinical study of HTX-011, Heron’s lead product candidate for the prevention of post-operative pain. HTX-011, which utilizes Heron’s proprietary Biochronomer® drug delivery technology, is a long-... 
Printer Friendly Version
03/13/15Heron Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results and Corporate Progress
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Mar. 13, 2015-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today reported fourth quarter and full year 2014 financial results and highlighted recent corporate progress. Fourth Quarter and Recent Corporate Progress: In February 2015, the Company initiated a Phase 1 single-ascending dose, placebo-controlled clinical trial of HTX-011 in healthy volunteers. This... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
05/14/15 11:20 a.m. PT
Heron Therapeutics Inc at Bank of America Merrill Lynch 2015 Health Care Conference
LocationLas Vegas, NV
Data provided by Nasdaq. Minimum 15 minutes delayed.